Caberol – Cabergoline 0.25 mg
Caberol is presented in the ORYVION catalog as a tablet formulation containing 0.25 mg of cabergoline per tablet, supplied in containers of 50 tablets. Cabergoline is a long-acting, orally active dopamine receptor agonist derived from ergot.
Its mechanism of action primarily involves stimulation of dopamine D2 receptors in the pituitary gland, reducing prolactin secretion. Its established medical applications include the treatment of hyperprolactinemic disorders, whether idiopathic or associated with pituitary adenomas.
Product Specifications:
Commercial name: Caberol
Listed compound: Cabergoline
Declared strength: 0.25 mg per tablet
Format: Tablets
Package contents: 50 tablets
Important Note:
Cabergoline can cause heart valve disease and fibrotic complications affecting the heart, lungs, or retroperitoneal tissues. Other adverse effects include nausea, dizziness, low blood pressure upon standing, and impulse-control disorders or compulsive behaviors.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.